| Literature DB >> 26277785 |
Osamu Kurihara1, Masamichi Takano1, Saori Uchiyama1, Isamu Fukuizumi1, Tetsuro Shimura1, Masato Matsushita1, Hidenori Komiyama1, Toru Inami1, Daisuke Murakami1, Ryo Munakata1, Takayoshi Ohba1, Noritake Hata1, Yoshihiko Seino1, Wataru Shimizu2.
Abstract
Contrast-induced nephropathy (CIN) is considered to result from intrarenal vasoconstriction, and occurs more frequently in impaired than in normal kidneys. It was hypothesized that iodinated contrast media would markedly change renal blood flow and vascular resistance in functionally impaired kidneys. Thirty-six patients were enrolled (32 men; mean age, 75.3 ± 7.6 years) undergoing diagnostic coronary angiography and were divided into two groups based on the presence of chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) of < 60 mL/min per 1.73 m(2) (CKD and non-CKD groups, n = 18 in both). Average peak velocity (APV) and renal artery resistance index (RI) were measured by Doppler flow wire before and after administration of the iodinated contrast media. The APV and the RI were positively and inversely correlated with the eGFR at baseline, respectively (APV, R = 0.545, P = 0.001; RI, R = -0.627, P < 0.001). Mean RI was significantly higher (P = 0.015) and APV was significantly lower (P = 0.026) in the CKD than in the non-CKD group. Both APV (P < 0.001) and RI (P = 0.002) were significantly changed following contrast media administration in the non-CKD group, but not in the CKD group (APV, P = 0.258; RI, P = 0.707). Although renal arterial resistance was higher in patients with CKD, it was not affected by contrast media administration, suggesting that patients with CKD could have an attenuated response to contrast media.Entities:
Keywords: arterial pressure; chronic renal insufficiency; contrast media; nephropathy
Mesh:
Substances:
Year: 2015 PMID: 26277785 PMCID: PMC5063113 DOI: 10.1111/1440-1681.12479
Source DB: PubMed Journal: Clin Exp Pharmacol Physiol ISSN: 0305-1870 Impact factor: 2.557
Patient characteristics
| Characteristic | eGFR ≥ 60 mL/min/1.73 m2 | eGFR < 60 mL/min/1.73 m2 |
|
|---|---|---|---|
| Patient number | 18 | 18 | |
| Age, years | 61.3 ± 13.2 | 75.3 ± 7.6 | < 0.001 |
| Sex, male (%) | 16 (89) | 16 (89) | 1.000 |
| Hypertension (%) | 14 (78) | 12 (67) | 0.711 |
| Hyperlipidaemia (%) | 15 (83) | 13 (72) | 0.691 |
| Diabetes mellitus (%) | 5 (28) | 10 (56) | 0.176 |
| Hyperuricemia (%) | 1 (6) | 9 (50) | 0.007 |
| Smoking (%) | 4 (22) | 2 (11) | 0.658 |
| Clinical presentation (%) | |||
| CAD | 14 (78) | 16 (89) | 0.658 |
| Prior MI | 7 (39) | 7 (39) | 1.000 |
| Medication (%) | |||
| Statin | 12 (67) | 11 (61) | 1.000 |
| ACE‐I | 3 (17) | 4 (22) | 1.000 |
| ARB | 9 (50) | 9 (50) | 1.000 |
| ß‐blockers | 9 (50) | 10 (56) | 1.000 |
| Calcium channel blockers | 11 (61) | 8 (44) | 0.505 |
| Diuretics | 4 (22) | 6 (33) | 0.711 |
| Laboratory data | |||
| Hb (g/dL) | 14.4 ± 2.0 | 12.7 ± 1.7 | 0.009 |
| UA (mg/dL) | 5.6 ± 1.0 | 6.2 ± 1.3 | 0.126 |
| BNP (pg/mL) | 33.7 ± 49.9 | 66.2 ± 46.8 | 0.052 |
| HbA1c (%) | 6.2 ± 1.2 | 6.8 ± 1.2 | 0.192 |
| Cre (mg/dL) | 0.84 ± 0.10 | 1.53 ± 0.83 | 0.001 |
| eGFR (mL/min/1.73 m2) | 71.2 ± 8.9 | 41.5 ± 14.6 | < 0.001 |
| Cystatin C (mg/L) | 0.86 ± 0.16 | 1.48 ± 0.61 | < 0.001 |
| LVEF (%) | 64.6 ± 11.8 | 60.2 ± 10.9 | 0.246 |
| Contrast media volume (mL) | 89.5 ± 24.4 | 75.2 ± 25.5 | 0.095 |
| Administration time (min) | 41.8 ± 11.5 | 41.3 ± 13.9 | 0.907 |
| Renal flow reserve | |||
| MBP (mmHg) | 96.3 ± 19.5 | 92.8 ± 9.6 | 0.488 |
| APV (cm/s) | 38.9 ± 8.1 | 31.5 ± 10.6 | 0.026 |
| RI (cm/s/mmHg) | 2.61 ± 0.63 | 3.46 ± 1.27 | 0.015 |
Values are numbers (%) or mean ± standard deviation.
ACE‐I, angiotensin converting enzyme inhibitors; APV, average peak velocity; ARB, angiotensin receptor blockers; BNP, brain natriuretic peptide; CAD, coronary artery disease; Cre, creatinine; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; HbA1c, haemoglobin A1c; MBP, mean blood pressure; MI, myocardial infarction; LVEF, left ventricular ejection fraction; RI, renal artery resistance index; UA; uric acid.
Changes in doppler flow wire findings
| Variable | Baseline | Post‐administration |
|
|---|---|---|---|
| MBP (mmHg) | 94.5 ± 15.2 | 92.2 ± 13.0 | 0.124 |
| APV (cm/s) | 35.2 ± 10.0 | 32.2 ± 9.0 | 0.001 |
| RI (cm/s per mmHg) | 3.04 ± 1.08 | 3.26 ± 1.10 | 0.014 |
| eGFR < 60 mL/min per 1.73 m2 | |||
| MBP (mmHg) | 92.8 ± 9.6 | 90.4 ± 10.9 | 0.082 |
| APV (cm/s) | 31.5 ± 10.6 | 30.2 ± 10.6 | 0.258 |
| RI (cm/s per mmHg) | 3.46 ± 1.27 | 3.51 ± 1.24 | 0.707 |
| eGFR ≥ 60 mL/min per 1.73 m2 | |||
| MBP (mmHg) | 96.3 ± 19.5 | 94.0 ± 14.9 | 0.404 |
| APV (cm/s) | 38.9 ± 8.1 | 34.1 ± 6.8 | < 0.001 |
| RI (cm/s per mmHg) | 2.61 ± 0.63 | 3.00 ± 0.90 | 0.002 |
Data are presented as mean ± standard deviations.
APV, average peak velocity; eGFR, estimated glomerular filtration rate; MBP, mean blood pressure; RI, renal artery resistance index.
Figure 1Simple linear regression analysis. Correlations of estimated glomerular filtration rate (eGFR) with average peak velocity (R = 0.545; P = 0001) and the artery resistance index (R = −0.627; P < 0001).
Serial changes in renal markers
| Renal function | Baseline | 24 h |
|
|---|---|---|---|
| eGFR ≥ 60 mL/min per 1.73 m2 | |||
| Creatine (mg/dL) | 0.78 ± 0.12 | 0.78 ± 0.97 | 0.577 |
| Cystatin C (mg/L) | 0.86 ± 0.16 | 0.83 ± 0.14 | 0.146 |
| eGFR < 60 mL/min per 1.73 m2 | |||
| Creatinine (mg/dL) | 1.40 ± 0.80 | 1.41 ± 0.76 | 0.635 |
| Cystatin C (mg/L) | 1.48 ± 0.61 | 1.45 ± 0.57 | 0.443 |
Data are presented as mean ± standard deviation.
eGFR, estimated glomerular filtration rate.
Figure 2Example of renal angiography and measurements by Doppler flow wire. (a) A 5‐French right coronary catheter is positioned at the ostium of the left renal artery, and the Doppler flow wire is introduced into the left renal artery. (b) Renal angiography. (c) The Doppler flow wire measures average peak velocity and renal artery resistance index.